In vitro disease modeling using embryonic stem cells or induced PSCs has shown considerable potential for applications in drug discovery, as well as for the elucidation of disease mechanisms 1,2 . Human PSC-based models can be particularly powerful where suitable animal models are not available or access to affected primary tissues is not feasible. Furthermore, the technology promises a personalized approach to the treatment of each individual by using cells that carry an exact copy of the patient's DNA. Although there has been considerable success in capturing disease phenotypes in vitro using human PSC technology 3 , the ability to recapitulate disease severity in a defined population, such as for individuals carrying identical genetic defects as is the case with FD, has not yet been demonstrated.
In vitro disease modeling using embryonic stem cells or induced PSCs has shown considerable potential for applications in drug discovery, as well as for the elucidation of disease mechanisms 1, 2 . Human PSC-based models can be particularly powerful where suitable animal models are not available or access to affected primary tissues is not feasible. Furthermore, the technology promises a personalized approach to the treatment of each individual by using cells that carry an exact copy of the patient's DNA. Although there has been considerable success in capturing disease phenotypes in vitro using human PSC technology 3 , the ability to recapitulate disease severity in a defined population, such as for individuals carrying identical genetic defects as is the case with FD, has not yet been demonstrated.
FD was one of the first genetic disorders to be faithfully modeled in PSC-derived lineages in vitro 4 . FD, also known as Riley-Day syndrome or hereditary sensory and autonomic neuropathy III, is a genetic disease affecting the development, function and survival of various NCderived lineages such as autonomic neurons and peripheral sensory neurons [5] [6] [7] . FD is an autosomal recessive disease and occurs almost exclusively in the Ashkenazi Jewish population, with a carrier frequency of 1 in 32 (ref. 8) . From birth, people with FD display a broad range of symptoms that include difficulties in swallowing or suckling, absence of fungiform papillae on the tongue, kyphoscoliosis, lack of tears, difficulties in regulating body temperature and blood pressure, reduced sensitivity to pain 9 and recurring vomiting crisis (dysautonomic crisis). Autopsy data show evidence of severely reduced cell numbers in the dorsal root ganglion (DRG) 9 and superior cervical ganglion (SCG) 10 . The clinical progression of FD indicates a degenerative component to the disease 11 in addition to any developmental defects. Nearly all (99.5%) people with FD carry an identical homozygous T>C point mutation in the splice donor (in intron 20) of IKBKAP, leading to partial skipping of exon 20 in the mutant IKAP protein and a reduction of wild-type protein. IKAP (also known as ELP1) is a component of the transcriptional elongator complex and is ubiquitously expressed. Why its impairment leads to an NC tissue-specific defect is not known. The plant hormone kinetin 12 , a food supplement, was shown to increase splicing of wild-type IKBKAP transcript in primary and PSC-derived NC cells 4 and is currently being tested in human FD patients 13 . FD was also the target of the first large-scale chemical screen in a PSC-based disease model that led to the identification of FD drug candidates including the α 2 -adrenergic receptor antagonist SKF-86466 (ref. 14) . SKF-86466 enhances IKBKAP mRNA and IKAP protein expression in PSC-derived NC cells, independently of splicing 14 .
While nearly all people with FD carry the same homozygous IKBKAP mutation, the severity of disease symptoms can vary. Here we use FD as a platform to address whether PSC technology is sensitive enough to predict disease severity in individuals carrying identical mutations in IKBKAP.
RESULTS

Modeling mild and severe FD in NC progenitor cells in vitro
To model disease severity, we obtained fibroblasts from three individuals with severe FD symptoms (S1-S3), three individuals with mild a r t i c l e s 1 4 2 2 VOLUME 22 | NUMBER 12 | DECEMBER 2016 nature medicine FD symptoms (M1-M3), one heterozygous carrier with no obvious symptoms (A1) and one healthy control subject (C1). Supplementary  Figure 1a and Supplementary Table 1 summarize available information used to classify severe and mild disease, including pain perception and frequency of dysautonomic crisis. We did not match sex and age, as there are no known sex-specific defects associated with FD, and age-related cellular features are thought to be largely reset after reprogramming 15 . We first characterized genotype ( Supplementary Fig. 1b ) and growth characteristics (Supplementary Fig. 1c ) in the fibroblasts but did not find any features that discriminated between disease severity at the primary fibroblast stage. We next reprogrammed fibroblasts from two patients per severity group (S2, S3, M1 and M2) as well as A1 and C1 into PSCs using nonintegrating, cytoplasmic RNA Sendai virus vectors expressing OCT4 (POU5F1), SOX2, KLF4 and cMYC (MYC) 16 (Supplementary Fig. 2a) . At least two PSC clones per patient were reprogrammed and characterized. However, owing to low inter-patient variability (data not shown), the majority of subsequent phenotypes were carried out with one clone per patient. PSC lines were characterized for pluripotency ( Supplementary Fig. 2b,c) and splicing of IKBKAP (Supplementary Fig. 2d ) as well as in vitro differentiation potential toward cell types representing the three germ layers that are unaffected in FD ( Supplementary Fig. 3a,b) .
To address whether the FD PSC model can capture differences between mild and severe FD, we first revisited three previously described phenotypes (IKBKAP missplicing, deficit in ASCL1 expression and migration defects) 4 at the NC stage. We initially followed a protocol, used in past FD studies, based on delamination and fluorescence-activated cell sorting (FACS)-based enrichment of NC precursors from early neural rosette structures 17, 18 (termed here rosette-NC (rNC) cells). All PSC lines generated neural rosettes and rNC cells at comparable efficiencies, with no differences in division rates, as previously reported 4, 14 (Supplementary Fig. 4a-d) .
To address whether cells at the NC progenitor stage can capture aspects of disease severity, we first measured IKBKAP splicing using qRT-PCR. We found that rNC progenitors from both severe (S2 and S3) and mild (M1 and M2) FD expressed a low ratio of wild-type to mutant IKBKAP transcripts, as compared to control cells (Fig. 1a) . Thus, neither the nature of the IKBKAP mutation nor the extent of alternative splicing can explain disease severity. We next investigated the functionality of rNC cells. We observed that rNC cells derived from people with severe FD did not migrate efficiently in a scratch assay 4 . In contrast, cells from people with mild disease migrated as efficiently as control cells (Fig. 1b) . To control for potentially differential proliferation, the number of cells that migrated into the scratch were normalized to the number of total cells in the picture. Furthermore, whereas rNC cells from severe FD expressed low levels of ASCL1, a marker for autonomic neuron progenitors, rNC cells from mild FD showed ASCL1 expression levels comparable to those in unaffected controls, both at the mRNA (Fig. 1c) and the protein (Fig. 1d) levels.
To further assess global changes in gene expression between mild and severe FD, we performed two RNA-sequencing studies. First, we compared PSCs and FACS-purified rNC cells from one biological replicate each from severe and mild disease and the control. Unsupervised global clustering as well as GO term analysis showed that at the rNC stage, samples from mild FD were more similar to control and distinct from severe FD samples, whereas in cells at the PSC stage those from mild and severe FD were distinct from control cells (Supplementary Fig. 5a,b) . These results were confirmed in a second RNA-sequencing study, conducted with two or three biological replicates ( Supplementary  Fig. 6a ). GO term analysis revealed that transcripts associated with extracellular region and cell adhesion terms were enriched in severe FD rNC cells, whereas transcripts associated with neurogenesis terms were enriched in samples from mild FD (Supplementary Fig. 6b,c) . However, none of the top differentially regulated genes between mild and severe rNC cells pointed to an obvious molecular explanation of disease severity (Supplementary Fig. 6d ).
Modeling mild and severe FD in NC progeny in vitro Next, we asked whether the differentiation disparity between mild and severe FD persists in NC derivatives, i.e., in cells relevant for patients after embryonic development. FD autopsy data revealed that numbers of sensory neurons (SNs) in the DRG and autonomic neurons (ANs) in sympathetic ganglia are reduced to 20% and 34% that of normal subjects, respectively 9, 10 , and thus are key targets for therapeutic intervention. The patients with severe FD studied here reported a pronounced decrease in pain sensation and report frequent vomiting episodes, which is probably a result of a deregulation of the autonomic nervous system. These symptoms are less common in mild FD (Supplementary Table 1) . Thus, we investigated the differentiation capacity of severe and mild FD lines into those NC derivative lineages. We derived FD SNs with a differentiation protocol 19 that yielded 33% BRN3A + SNs (Supplementary Fig. 7a ). By day 12 of differentiation, it was obvious from an examination of cell morphology that lines from patients with severe FD were deficient in making SNs. In contrast, both mild FD and control cultures yielded a dense network of neuronal processes (Supplementary Fig. 7b ). Immunostaining and quantification of SNs, which are BRN3A + TUJ1 + at day 14, confirmed these results (Fig. 2a,b) . A temporal expression analysis of SOX10 established the NC origin of SNs (Supplementary Fig. 7c) . One potential reason for the inability of severe lines to generate SNs is a lower splicing ratio of IKBKAP 20 . However, IKBKAP ratios were low in SNs from both severe and mild FD (Fig. 2c) . Thus, IKBKAP expression alone does not explain the SN phenotype or the differences between mild and severe FD.
To address FD phenotypes in ANs we first established a differentiation protocol (Supplementary Fig. 7d ), as no reliable published reports were available. NC cells are induced by activating WNT signaling at day 2 of differentiation using a modified dual-SMAD inhibition protocol 19, 21 . At day 11, the cells were FACS isolated on the basis of expression of α 4 -integrin receptor (CD49D), which marks SOX10 + NC cells in this differentiation paradigm 22 (Supplementary Fig. 7e ). Gene expression analysis by qRT-PCR at days 30, 40, 50 and 60 and immunostaining showed strong upregulation of sympathetic AN markers, such as ASCL1, PHOX2A, SCG10 (STMN2), TH and DBH 23 , whereas markers of related cell types, such as parasympathetic ANs (CHAT) 23 , enteric neurons (EDNRB) 24 and sensory placode lineages (SIX1) 25 were only moderately induced ( Supplementary Fig. 8a,b) . However, analysis of mature markers such as autonomic ganglia-specific acetylcholine receptor, encoded by CHRNA3 and CHRNB4, and vesicular monoamine transporter, encoded by VMAT1 (SLC18A1) and VMAT2 (SLC18A2), was largely negative (Supplementary Fig. 8d ), and we did not detect noradrenaline release by HPLC (data not shown), suggesting an immature AN-like phenotype. A recent study showed that human embryonic stem (HES) cell-derived sympathetic neurons express such late markers only upon co-culture with mouse cardiomyocytes, further supporting our hypothesis 26 . When we applied the AN-like protocol to FD PSC lines, we found that cells from severe FD could not effectively generate CD49D + NC cells, in contrast to control and mild FD cells (Fig. 2d) . In fact, severe FD CD49D + NC cells survived poorly, whereas mild FD and control CD49D + NC cells generated AN-like cells (PHOX2A + TUJ1 + ) by day 25 ( Supplementary Fig. 9a ) at efficiencies of 10-25% of TH + and ASCL1 + cells within the cultures (Supplementary Fig. 9b ). The non-AN-like cell fraction comprised mostly nonproliferating (Ki67 -), myofibroblast-like cells (αSMA + ) with a fraction of SN contaminants (BRN3A + ISL1 + ) ( Supplementary Fig. 9c,d ).
Neurodegeneration in mild and severe FD We next aimed to define cellular phenotypes that can discriminate mild disease from controls and explain why patients with mild FD have disease symptoms. FD is a progressive disease, as illustrated by the deterioration in pain perception with increasing age 6, 11 . Therefore, we tested whether cells from mild FD show primarily neurodegenerative rather than developmental phenotypes. We replated differentiated FD SNs on day 12 at equal densities ( a r t i c l e s significantly. Similarly, the few SNs generated from severe FD died (Fig. 3a,b) . We also found an increase of cleaved caspase-3 that was paralleled by loss of BRN3A + cells in FD but not control cells (Supplementary Fig. 10a ). To investigate potentially contaminating cells in the cultures, we stained for markers of progenitors (SOX10 and SOX2) and proliferation (Ki67), and found little of either. Most nonSNs in the cultures were α-SMA + nonproliferating, myofibroblast-like cells (Supplementary Fig. 10b ). Finally, we assessed the survival of AN-like cells from mild FD over time. These cells did not show any defects in survival for up to 50 d, as assessed on the basis of TH + and ASCL1 + cell numbers. Even when cells were stressed by removal of growth factor or addition of toxin (carbonyl cyanide 3-chlorophenylhydrazone (CCCP)), neither mild FD nor control AN-like cells died ( Supplementary Fig. 11a,b) . Future studies may determine whether the failure to detect degenerative phenotypes is due to the immaturity of AN-like cells ( Supplementary Figs. 8d and 11a) . Together, these data suggest degeneration as the primary culprit for mild FD, whereas both developmental and degenerative defects characterize severe FD.
We have previously identified positive effects of kinetin 12 and the α 2 -adrenergic receptor antagonist SKF-86466 on IKBKAP splicing in FD rNC cells 14 . However, rNC phenotypes represent a neurodevelopmental paradigm that may not translate to FD patients, who no longer harbor significant numbers of NC progenitors. Thus, we asked whether neurodegeneration could be halted in SNs from mild FD. After we verified the expression of α 2 -adrenergic receptors (Supplementary Fig. 12a ), SNs were differentiated and treated with kinetin, SKF-86466 or vehicle (DMSO) starting from day 12, and their survival was assessed. SNs from mild FD treated with either drug survived, whereas DMSO-treated cells progressively died (Fig. 3c) . This rescue effect was correlated with an increase in IKBKAP splicing transcripts in cells treated with kinetin but not SKF-86466 (Supplementary Fig. 12b ). These results indicate potential treatment options for patients with FD after birth and support efforts to bring kinetin into the clinic 13 .
Repair of IKBKAP yields insight into disease severity Evidence in FD animal models points to the importance of IKBKAP expression levels. Conditional knockout mouse models suggest that phenotype severity is a direct result of Ikap levels 27, 28 . To determine the role of IKBKAP expression in human FD disease severity, we first looked at IKBKAP splicing. We observed that the ratio of wild-type to mutant IKBKAP transcripts was equally low for severe and mild FD in PSCs (Supplementary Fig. 2d ), rNC cells (Fig. 1a) , SNs (Fig. 2c) , primary fibroblasts and PSC-derived endoderm, cardiomyocytes and cortical neurons (Supplementary Fig. 13a) .
At the protein level, PSCs from severe and mild FD showed lower IKAP levels than controls (Supplementary Fig. 13b) . However, at the rNC stage, mild FD and control lines showed comparable IKAP protein levels, whereas cells from severe FD showed lower levels ( Supplementary Fig. 13b ). These results match IKBKAP splicing ( Fig. 1a and Supplementary Fig. 2d ) and RNA-sequencing data ( Supplementary Figs. 5 and 6) , which show that PSCs from mild and severe disease show comparable expression levels, whereas mild FD rNC cells show expression comparable to that of control cells. Thus, it is possible that increased IKAP protein levels in rNC cells could contribute to protecting mild FD cells from the early developmental phenotypes characteristic of severe FD.
To confirm that the inability of severe FD cells to generate NC precursors and derivatives is specific to the IKBKAP mutation, we used the CRISPR-Cas9 system 29, 30 to repair the mutation. We identified three clones that showed heterozygous repair (targeting frequency of 10%) ( Supplementary Fig. 14a-c) . No Cas9 off-target cutting was detected at the top 10 predicted sites (Supplementary Fig. 15a,b) . To compare those gene-corrected clones to a heterozygous patient line, we established a PSC line from a heterozygous carrier with the FD-associated mutation (A1). Analysis of IKBKAP splicing in gene-targeted clones revealed higher splicing ratios than in the parental S2 line and were comparable to splicing in A1 (Fig. 4a,b) . Analysis of IKAP protein levels yielded similar results (Supplementary Fig. 14d,e) . Heterozygous carriers do not show FD disease symptoms 5 , so we tested whether our in vitro FD phenotypes reverted in gene-corrected cells. Notably, both ASCL1 expression in rNC cells (Fig. 4c) and CD49D expression during early NC induction (Fig. 4d) were restored in gene-corrected clones to wild-type or A1 levels. These results confirm that the IKBKAP point mutation is responsible for early developmental NC disease phenotypes in severe FD. Next, we investigated whether genetic rescue of IKBKAP would revert differentiation defects of NC derivatives, i.e., SNs. Notably, SN differentiation was not restored in any of the three genetic rescue lines (Fig. 4e) . These data suggest that FD phenotypes downstream of the NC are not caused solely by the IKBKAP mutation.
Candidate modifier mutations may contribute to FD severity To identify candidate modifier genes in severe FD, we performed whole-exome sequencing in all six FD cell lines (S1-S3 and M1-M3).
We searched for genes that showed nonsynonymous coding variants (not necessarily the same variants) in S1, S2 and S3 following a model of complete penetrance given the small sample size. We focused on rare variants, with a minor allele frequency (MAF) < 1% in public databases (<1% in the 1000 Genomes Project (1KG) and in the Exome Aggregation Consortium (ExAC) browser). We further ranked the candidate genes on the basis of the predicted impact of each variant by combined annotation-dependent depletion (CADD) 31, 32 and the number of damaging mutations found in healthy individuals for each gene by gene-damaging index (GDI) 33 . We also took into account the mutation significance cutoff (MSC), a gene-level specific cutoff for CADD scores 34 . First, testing an autosomal-dominant mode of inheritance, we identified seven candidate modifier genes harboring homozygous variations common to all severe FD patients. However, the same variations were also found in the mild FD samples (Fig. 5a, Supplementary Fig. 16 and Supplementary Table 2 ). Second, we tested an autosomal-recessive mode of inheritance and identified 23 candidate genes, 20 of which were also mutated in mild FD and thus filtered out. Three candidate genes remained: LAMB4, KIAA1211 and FAT2. Within the severe FD sample, these three genes carried variations predicted to be damaging (CADD score > MSC score) 34 . LAMB4 had the lowest GDI score and was our top candidate ( Fig. 5a, Supplementary Fig. 16 and Supplementary Table 2 ). In a separate analysis based on incomplete penetrance but taking into account close functional relatedness to IKBKAP as revealed by the gene's connectome 35 , few additional candidates were identified from the initial list of affected genes, including URI1, LCA10 (CEP290), MSH3 and YEATS2. We found that LAMB4 (encoding laminin β4) harbors one missense variant in S1 and shares another between S2 and S3 (Supplementary Table 2 and Supplementary Fig. 17 ). Laminins are secreted heterotrimeric (α-, β-and γ-chains) proteins of the extracellular matrix. They greatly influence the differentiation, migration and adhesion of cells within tissues and have important roles in neuronal development, such as axonal growth. To date, no laminin trimer containing laminin β4 has been identified, and its function is largely unknown. The encoding gene is expressed most highly in the SCG and DRG, thus it may have a role in the development of tissues particularly affected in FD and that show clear phenotypic differences between mild and severe FD in our model. We used our RNA-sequencing data from rNC cells to investigate whether the mutations in the three top candidate modifier genes lead to differential gene expression in severe, mild and control rNC cells. Only FAT2 showed significantly higher expression in severe FD, particularly in exon 9, where S2 had a mutation (Supplementary Fig. 17 ), indicating that investigating the candidate mechanisms of action will involve in-depth molecular and functional studies in the future. Experiments from this study are summarized in Supplementary Table 3. DISCUSSION FD has been at the forefront of PSC-based disease modeling 4 and drug discovery 14 efforts. Here we used FD as a model to address a major challenge for PSC research-the ability to capture disease severity-as an important step toward implementing it in personalized medicine. FD is particularly relevant to this question, as it is caused by the same point mutation in nearly all FD patients; yet it can present with mild or severe symptoms and a variable slope of progression.
Our study demonstrates that it is possible to recapitulate disease severity in vitro and that a strong neurodevelopmental phenotype is restricted to patients with severe FD. In contrast, severe and mild FD cells display neurodegenerative phenotypes, as illustrated by progressive SN loss. We postulate that severe FD constitutes a genetic subdisease within FD, as we found some secondary mutations that were unique to severe FD and could be the cause of additional and/or more severe symptoms (Fig. 5b) . Our work raises the question whether, in human FD, genetic background differences represent distinct disease subtypes or the contribution of more minor disease modifiers. Future studies will be required to address in more detail the molecular mechanisms explaining the differences between mild and severe FD. Such studies could also address whether it is possible to identify phenotypes representing intermediate disease severity at the cellular level, though there are currently no obvious criteria to clinically define FD with intermediate severity. It is notable that kinetin and SKF-86466 were capable of inhibiting degeneration in mild SNs. Those results provide an additional impetus to pursue the clinical translation of those compounds in FD. Finally, our results may catalyze efforts to model severity in other genetic disorders. Future studies should analyze much larger cohorts of patient-derived PSC lines for a given disease, without a priori clinical information on disease severity and under fully blinded conditions. Such a study may confirm stratification along existing clinical subgroups or yield additional subgroups not captured in clinical data sets. The ability to model severity in a genetically defined disease is an important step in moving PSC research toward a new era of personalized medicine that captures the biology of individual patients.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Accession codes. Gene Expression Omnibus: FASTQ files for RNA sequencing were deposited under accession numbers GSE67073 (first round) and GSE77513 (second round). dbGAP: whole-exome sequencing files were deposited under accession number phs001233. v1.p1. 
ONLINE METHODS
FD fibroblasts. Fibroblasts were purchased from Coriell under catalog numbers S1 = GM04959, S2 = GM04899, S3 = GM04589, M1 = GM02341, M2 = GM02342, M3 = GM02343, C1 = AG02602, C2 = GM00316, A1 = GM04895, A2 = GM04665, A3 = GM04897 and cultured in fibroblast medium (DMEM; Gibco, 11965-092) and 10% FBS (Atlanta Biologicals, S11150), 0.5% l-glutamine (Gibco, 25030-081) and 0.5% Pen-Strep (Gibco, 15140-122)). For genotyping the FD-associated mutation, gDNA was extracted using the DNeasy Blood and Tissue kit (Qiagen, 69506) and a ~500-bp PCR product (PCR primers: 5′ CCATAAGGCTCAAAGCGAAA and 5′ TGAGTGTCACGATTCTTTATGC) was sequenced (primers: 5′ GAAAGTCAAGATAAATATAGAGAAC and 5′ TCTGCTAGGAATCTCCACTA). To establish fibroblast growth, each line was seeded at 100,000 cells per well in a 6-well plate and cells were counted every day. For IKBKAP splicing, fibroblast RNA was harvested in TRIzol Reagent (Ambion, 15596018). 1 µg RNA was used to generate cDNA (QuantiTect Reverse Transcription kit, Qiagen, 205313) and SYBR green (Applied Biosystems, 4309155) was used for qRT-PCR on an Eppendorf Mastercycler, according to the manufacturer's instructions, with the following primers: wild-type IKBKAP, 5′GCAGCAATCATGTGTCCCA and 5′ACCAGGGCTCGATGATGAA; mutant IKBKAP, 5′CACAAAGCTTGTATTACAGACT and 5′GAAGG TTTCCACATTTCCAAG. All results were normalized to 18S control (primers: 5′GGCCCGTAATTGGAATGAG and 5′GCTATTGGAGCTGGAATTAC). Cycling parameters were described previously 6, 14 .
Reprogramming, PSC culture and characterization. Cells were fed daily with fibroblast medium. On day 7, the cells were dissociated using trypsin-EDTA (Gibco-Life Technologies, 25300-054) and replated onto 10-cm MEF-coated plates (MEF from GlobalStem, GSC-6105M) in HES medium supplemented with 0.5 mM valproic acid (VPA) (Tocris Bioscience, 2815), as described in Zeltner et al. 18 . Cells were fed daily with HES medium + VPA until day 14, then with HES medium only. Between day 20 and day 40, PSC colonies were manually picked, expanded and frozen. PSCs were fed daily with HES medium and passaged manually or with trypsin-EDTA 18 approximately once per week onto MEFs. PSC cultures were tested every other week for mycoplasma contamination. For the characterization of PSC lines, cells were immunostained with antibodies to Oct-4 (mIgG2b, Santa Cruz, sc-5279), Nanog (goat, R&D, AF1997) and Sendai virus (rabbit, MBL International, PD029). IKBKAP splicing in PSCs was conducted as described for fibroblasts. The karyotypes of the PSC clones were normal except at high passages in S3 and M2.
In vitro differentiation of PSCs. HES medium, KSR differentiation medium, N2 differentiation medium, Matrigel dish coating and poly-l-ornithine hydrobromide (PO, Sigma-Aldrich, P3655), laminin-1 (LM, R&amp;D Systems, 3400-010-01) and fibronectin (FN, BD Biosciences, 356008) (PO/LM/FN) dish coating, plating of PSC for differentiation and day 0 to day 11 dual-Smad inhibition differentiation were all as described in Zeltner et al. 18 . CNS neuron differentiation. For in vitro differentiation to CNS neurons, PSCs were detached using Accutase (Innovative Cell Technologies, AT104) for 20 min. at 37 °C, washed twice with 1× PBS and plated onto Matrigel (BD, 354234)-coated 6-well-plates in HES medium supplemented with 10 µM Y-27632 dihydrochloride (Tocris, 1254). When 100% confluency was reached, the cells were fed daily with KSR or N2 medium supplemented with LDN193189 (Stemgent, 04-0074) and SB431542 (Tocris, 1614) 18 . On day 11 cells were detached with Accutase, |washed twice and replated onto plates coated with PO/LM/FN in droplets of 100,000-150,000 cells per 10 µl as described 18 , in N2 medium supplemented with 0.02 µg/ml BDNF (R&D Systems, 248-BD), 0.2 mM ascorbic acid (Sigma-Aldrich, A4034) and 0.1 µM purmorphamine (Stemgent, 04-0009). On day 13 the cells were fed with N2 medium + ascorbic acid (AA) + brain-derived neurotrophic factor + purmorphamine; on days 15, 17 and 19 they were fed with N2 medium + AA + BDNF + 0.01 mM DAPT (R&D, 2634/50); and on day 20 they were fixed with 4% PFA (Affymetrix, 19943) and immunostained with antibodies to TBR1 (rabbit, Millipore, AB10554) and TUJ1 (mIgG2a, Covance, MMS-435P-250).
Endoderm differentiation. PSCs were plated as described 18 . Cells were fed daily with RPMI medium containing Glutamax (Invitrogen, 61870-036) supplemented with 0.5% FBS and 100 µg/ml activin A (R&D, 338-AC), fixed on day 5 and immunostained for SOX17 (goat, R&D, af1924) and DAPI.
Mesoderm and cardiac differentiation. Cardiac differentiations were done as described previously 36, 37 with the following modifications: RPMI 1640 (Life Technologies, 11875-093) and B27 (Life Technologies, 17504044) was used instead of StemPro34. Embryoid bodies (EBs) were treated with 10 ng/ml activin A (R&D Systems, 338-AC) and 10 ng/ml BMP4 (R&D Systems, 314-BP) from day 1 to day 3, followed by 10 µM XAV939 (Stemgent, 04-0046) from day 3 to day 5. Differentiation cultures were assessed for mesoderm formation by flow cytometry staining for KDR and VEGFR2 (Alexa Fluor 647 anti-human CD309, BioLegend, 7D4-6) and PDGFRA (PE anti-human CD140a, BioLegend, 16A-1). The differentiations were carried on until day 20 in RPMI 1640 (Life Technologies, 11875-093) + B27 (Life Technologies, 17504044) and stained for the anti-cardiac isoform of troponin T (cTnT) (Thermo Scientific Lab Vision, clone 13-11) by flow cytometry as well as plated onto plastic dishes and stained for cTnT via immunofluorescence (IF) on day 30 of differentiation.
For quantification of neurons, endoderm and cardiac cells, images from two wells of each of 3-5 differentiations were counted for TBR1 + TUJ1 + cells or SOX17 + or troponin T + , respectively, and the percentage of total DAPI + cells was reported.
rNC cell differentiation. rNC cell differentiation, FACS isolation and HNK1, PAX6, αAP2a, ASCL1 and TUJ1 staining were carried out as described 18 . To measure the proliferation rate, FACS-isolated rNC cells were plated at 30,000 cells per well in a 96-well plate 18 . 24 h later they were fed with N2 + FGF2 + EGF medium containing EdU using the Click-iT Plus EdU Alexa Fluor 555 Imaging kit (Life Technologies, C10638). 48 h later cells were fixed and stained according to the manufacturer's instructions, and EdU + DAPI + cells were counted. IKBKAP splicing PCR was conducted for fibroblasts. The migration (scratch assay) was conducted as described 18 . Briefly, FACS-isolated rNC cells were plated in PO/ LM/FN-coated 96-wells at 20,000-60,000 cells per well and scratched 24 h later using a 200-µl pipet tip. 6-8 wells were fed with medium containing 10 ng/ml Hoechst 33342 trihydrochloride, trihydrate (Invitrogen, H3570) and reference pictures (0 h = before migration) were taken immediately. The medium in the other wells was changed to remove dead cells. Cells were allowed to migrate for 48 h and stained with Hoechst 33342 before pictures were taken. The number of migrated cells was quantified automatically by the Konstanz information miner (KNIME) workflow 38 . Results are expressed as percentage of cells migrated into a region of interest (ROI) of the total number of cells per picture. ASCL1 qRT-PCR was conducted on RNA isolated from FACS-sorted rNC cells on day 18 of differentiation. Taqman gene expression assay (ABI, 4304437) for ASCL1 (primers: ABI, Hs00269932_m1 (ASCL1) and 4326321E (HPRT)) was conducted on an Eppendorf Mastercycler. Fold changes were calculated using the comparative threshold cycle (Ct) method (∆∆Ct method) and then normalized to expression in undifferentiated HES cells. Immunostaining of rNC cells was conducted 1 week after FACS isolation, as described 18 .
Peripheral SN differentiation. SN differentiations were carried out as described in Chambers et al. 19 , with a few modifications. Briefly, PSC were plated on Matrigel-coated dishes, and differentiations were induced once 100% confluency was reached, using a gradient of KSR and N2 differentiation medium supplemented with LDN193189 and SB431542 (ref. 18) . From day 2 to day 11, 1.5 µM CHIR99021 (GSK3β inhibitor, activation of Wnt signaling; Stemgent, 04-0004), 10 µM SU5402 (FGF inhibition; BioVision, 1645-1) and 10 µM DAPT (Notch inhibition; Tocris, 2634) were added to the medium. On day 12, cells were detached using Accutase, washed twice and replated into PO/LM/FN-coated 96-wells at 280,000 cells per well in N2 differentiation medium supplemented with 50× B-27 (Life Technologies, 12587-010), 20 ng/ml BDNF (R&D Systems, 248-BD), 20 ng/ml GDNF (Peprotech 450-10), 25 ng/ml β-NGF (Peprotech, 450-01), 100 µg/ml Primocin (InvivoGen, ant-pm-2), 0.6 µg/ml laminin-1 (R&D Systems, 3400-010-1), 0.6 µg/ml fibronectin (Fisher Scientific, CB40008A-BD) and 10 µM Y-27632 (Tocris, 1254). For maintenance, cells were fed the same medium without Y-27632 every 2-3 d. On days 14, 17, 20, 23 and 26 the cells were fixed in 4% PFA and stained with DAPI (1:1,000, Sigma-Aldrich, D9542-5M) and antibodies to BRN3A (mIgG1, 1:100, Millipore, MAB1585), TUJ1 (rabbit, 1:1,000, Covance, MRB-435P-100), cleaved caspase-3 (rabbit, 1:100, TGAGGAAGCCAGTCCAC, NZ73fseq-5′CCCTTACCCAGGAGGTCACT. ID#7, NZ74f-5′GGCTCTCTGCCCAATTCATA, NZ74r-5′TGGGGATTT TTCCCCTTTAG, NZ75f-5′AACCCTCCATCCCACCTTAC, NZ75r-5′CA GGCACACCCCATTTTAAG, NZ76fseq-5′AGAAAGCTTGCCATCCTTGA, NZ77fseq-5′TTCTGGAAGCAGTAGCACCA. ID#8, NZ78f-5′CAGCTTT GGGTCCTATTTGC, NZ78r-5′AATGGCCCCTTGGTGAATAC, NZ79f-5′TC TGGCTGGAATGATGTTTG, NZ79r-5′TCTTGGTCCATCCAAAATGG, NZ80fseq-5′CTGCCTCATGGTGAAGAGGT, NZ81fseq-5′TCTCCTTATCC ATCTGCCTCA. ID#17, NZ82f-5′GCAGCTGCAGGATAGGGTAG, NZ82r-5′GACAGCTCCTGCATCAGGTT, NZ83f-5′ATAGGGTAGCCCTCCTCCAC, NZ83r-5′GAGGACAGCTCCTGCATCA, NZ84fseq-5′TACTGCGCTTGCT CAAAAAC, NZ85fseq-5′ACATTCTCGCGAAGGGTCT. ID#22, NZ86f-5′G CCTCAGCCTGTTGTTCTTC, NZ86r-5′CGATCTCGTGGCTGATAACC, NZ87f-5′TGTTCTTCGTCCTGGCCTAC, NZ87r-5′GTCGATCTCGTGGC TGATAA, NZ88fseq-5′GCCTTCCTCTTCTCCATCG, NZ89fseq-5′TCAA CAACCTCAACGGCTTC. No mutations were detected in any of the sequences. In ID#3, S2-rescue1 and in ID#22, all three clones did not yield PCR products or sequences that would allow the determination of mutations.
Western blot analysis. For protein analysis of NC cells, HNK1 + p75 + cells were isolated by cell sorting and cells were pelleted and snap frozen. PSCs were harvested by scrapping after removal of the MEF layer. To extract protein, the cell pellet was resuspended in 1× RIPA buffer (Sigma-Aldrich, R 0278) containing 1× Halt Protease and Phosphatase inhibitor cocktail (Thermo Fisher, 87786). In a few samples, to obtain sufficient protein for analysis, cell pellets from two separate NC inductions were combined or FACS isolation was conducted on single-positive cells. For western blotting, a total of 10 µg protein was mixed with 4× Novex sample buffer (Thermo Fisher, NP0007) and 10× NuPAGE reducing agent (Thermo Fisher, NP0004) to a final concentration of 1×. Lysates were run on 4-12% pre-cast Bis-Tris gels (Novex, NP0322BOX), transferred onto PVDF membranes (Thermo Fisher, 88518) and blocked with 5% milk. Antibodies used for western blotting analysis were specific to β-actin (Sigma-Aldrich, A2228) and IKAP (GeneTex, GTX110274). Band intensity was measured with NIH ImageJ and normalized to β-actin. For the quantification of western blotting in Supplementary Figures 13b and 14d ,e, control lines S2 and HES represent the same data points, run on the same gels, for easier comparison.
RNA sequencing. Global gene clustering. For the first round, paired-end RNA sequencing was performed on H9-ESCs, mild FD PSCs, severe FD PSCs and subsequent NC progenitors with no replicates. Reads were mapped to the human genome build hg19 using TopHat software 40 . Reads that aligned with no more than 2-bp mismatches were accepted for downstream analysis. For the second round, the FASTQ files were mapped to the target genome (UCSC hg19) using the rnaStar aligner 41 , which maps reads genomically and resolves reads across splice junctions. We used the two-pass mapping method 42 , in which reads are passed twice. The first mapping pass uses a list of known annotated junctions from Ensembl. Novel junctions found in the first pass are then added to the known junctions, and a second mapping pass is done. After mapping, we computed the expression count matrix from the mapped reads using HTSeq (http://www-huber.embl.de/users/anders/HTSeq/doc/overview. html) and one of several possible gene model databases. The raw count matrix generated by HTSeq were then processed using the R Bioconductor package DESeq (http://www.huber.embl.de/users/anders/DESeq/) to normalize the full data set and analyze differential expression between sample groups. A heat map was generated using the heatmap.2 function from the gplots R package. The data plot was the mean centered normalized log 2 expression of the top 100 significant genes. For simple hierarchical clustering the correlation metric was used (Dij = 1 − cor(Xi,Xj)) with the Pearson correlation on the normalized log 2 expression values.
GO term analysis. Genes that showed significantly different expression between the rNC and PSC states were subjected to GO term analysis using the DAVID functional annotation tool (https://david.ncifcrf.gov/tools.jsp). The occurrence of GO terms with a Bonferroni score ≤0.05 were quantified. Certain GO terms were combined to score 10 GO terms per line; the numbers were displayed as percentages of the total, in pie charts. The analysis was done independently for each of the FD severity groups (S, M, C).
Whole-exome sequencing. 500 ng DNA was captured by hybridization using the SureSelect XT HumanAllExon V4 (Agilent). Samples were prepared according to the manufacturer's instructions. PCR amplification of the libraries was carried out for 6 cycles in the pre-capture step and for 7 cycles after capture. Samples were barcoded and run on a Hiseq 2500 in a 50-bp/50-bp paired-end run, using the TruSeq SBS Kit version 3 (Illumina). The average number of read pairs per sample was 77 million, the average duplication rate was 2.1%, and the mean target coverage was >100×. Intergenic, intronic and synonymous variations and UTRs were removed in our initial search for variants in the severe FD samples. In an autosomal recessive approach, 26 genes carried homozygous variations in all 3 severe FD samples, with a MAF of <1% in the 1000 Genomes database. 63 variations were dismissed owing to their high frequency (MAF > 1%) in the ExAC database, leaving 7 genes carrying 14 variations as candidates. All 7 genes carried the same variations in the mild FD samples and were therefore discarded as candidate modifier genes. In an autosomal-dominant approach, 77 genes carried heterozygous variations in all 3 severe FD samples, with a MAF of <1% in the 1000 Genomes database. 446 variations were removed on the basis of their high frequency (MAF > 1%) in the ExAC database, leaving 23 genes carrying 51 variations as candidates genes mutated in all severe FD samples. Of these, 15 carried the same variations in the mild FD samples and were therefore discarded as candidate modifier genes. Five of the remaining eight genes harbored variations predicted to be damaging with a frequency <1% in the 1000 Genomes database and were therefore not prioritized as candidates under a complete penetrance hypothesis. FAT2, KIA1211 and LAMB4 thus were the primary hit candidates. A connectome analysis using IKBKAP as the core gene on the Human Gene Connectome Server (http://hgc.rockefeller.edu/) and including all of the initial candidate genes identified URI1, LCA10, MSH3 and YEATS2 as being closely related to IKBKAP and therefore of potential interest for further studies.
Statistical analysis. All statistical comparisons between PSC lines were done using one-way ANOVA. Multiple comparisons were done among samples in each figure. The test specifics described in the figure legends were compiled from pooling data from the two severe, two mild or two control lines, respectively. For 
